UNSPSC 51373007: Pentazocine lactate

This classification denotes an opioid receptor agonist with the molecular formula C19H27NO.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P2XIB510O, chemically known as 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, (2alpha,6alpha,11r*)-, compd. with 2-hydroxypropanoic acid (1:1) but more generally known as pentazocine lactate, which bears US NIH Compound Identifier 66386.

UNSPSC 51373007 Pentazocine lactate is a Commodity code with minimal recent state and local procurement activity directly tied to this specific opioid analgesic. The recent opportunities posted under this code reflect a mismatch between the code's nominal scope and actual purchasing intent. Rather than purchases of pentazocine lactate itself, state and local buyers have tagged solicitations for naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals—products that do not align with pentazocine's therapeutic class or supply chain. This suggests either cataloging errors in the posting systems or a broader pharmaceutical procurement family where the code assignment does not reflect the substance or service being acquired.

The issuing bodies reflected in these opportunities span state health agencies and multistate cooperative purchasing vehicles: Seminole County, Florida (health department procurement); the Texas Health and Human Services Commission (state-level RFI); and the Minnesota Multistate Cooperative Purchasing Alliance (cooperative vehicle for Oregon and Minnesota participation). Geographic activity appears concentrated in Florida, Texas, and the Upper Midwest, though the cooperative purchasing framework extends reach across multiple jurisdictions. Representative recent opportunities include Seminole County's July 2026 IFB for naloxone and drug deactivation systems (1,900 units annually, quarterly delivery, due Jul 26, 2023); the Texas HHS Commission's April 2026 RFI on direct-to-manufacturer prescription programs; and MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products via authorized wholesalers, due Mar 26, 2026. The code shows recent activity but little clarity on pentazocine-specific demand—prospective vendors should treat this code as low-relevance unless pursuing broader pharmaceutical supply or opioid-management contracts where secondary assignment occurs.